Novartis Typhoid Vaccine Deal With India’s BioE Shows New Licensing Model
This article was originally published in The Pink Sheet Daily
Biological E Limited will develop Novartis’ Vi-CRM197 beyond Phase II; the firm will gain rights to a second vaccine against typhoid and paratyphoid upon completion of proof of concept studies.
You may also be interested in...
Phase II study is ongoing in Pakistan, a year after Novartis convinced the Pakistani government to lift its ban on clinical trials. Antimalarials with a different mechanism of action than Coartem are in Phase I and II trials.
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.